References
- Pisoni RL, Bragg-Gresham JL, Young EW, Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004;44(1):94–111.
- Tompson C. UK renal registry 12th annual report (December 2009): Chapter 1 summary of findings in the 2009 UK registry report. Nephron Clin Pract. 2010;115(Suppl. 1): 1.
- NICE. National Costing Report: Anaemia management in people with CKD 2006 Mid City Place, London: NICE (National Institute of Clinical Excellence), Available at: www.nice.org.uk/CG039. Accessed February 25, 2011.
- Deicher R, Horl WH. Differentiating factors between erythropoiesis-stimulating agents – A guide to selection for anaemia of chronic kidney disease. Drugs. 2004;64(5):499–509.
- National Kidney Foundation. IV. NKF-K/DOQI Clinical practice guidelines for anemia of chronic kidney disease: Update 2000. Am J Kidney Dis. 2001;37(Suppl 1):S182–S238.
- Locatelli F, Aljama PA, Barany P, Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004;19:1–47.
- Halstenson CE, Macres M, Katz SA, Comparative pharmacokinetics and pharmacodynamics of epoetin-alfa and epoetin-beta. Clin Pharmacol Ther. 1991;50(6):702–712.
- Sorgel F, Thyroff-Friesinger U, Vetter A, Vens-Cappell B, Kinzig M. Biosimilarity of HX575 (human recombinant epoetin alfa) and epoetin beta after multiple subcutaneous administration. Int J Clin Pharm Ther. 2009;47(6):391–401.
- Ifudu O, Cohen LS, Mayers JD, Joseph A, Delano BG, Friedman EA. Residual renal function modulates response to erythropoietin in chronic renal insufficiency. Dial Transplant. 2001;30(6):344–354.
- Brockmoller J, Kochling J, Weber W, Looby M, Roots I, Neumayer HH. The pharmacokinetics and pharmacodynamics of recombinant-human-erythropoietin in hemodialysis-patients. Br J Clin Pharmacol. 1992;34(6):499–508.
- Lopez-Gomez JM, Perez-Flores I, Jofre R, Presence of a failed kidney transplant in patients who are on hemodialysis is associated with chronic inflammatory state, and erythropoietin resistance. J Am Soc Nephrol. 2004;15(9)2494–2501.
- Kaysen GA, Muller HG, Ding J, Chertow GM. Challenging the validity of the EPO index. Am J Kidney Dis. 2006; 47(1):157–166.
- Lopez-Gomez JM, Portoles JM, Aljama P. Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality. Kidney Int Suppl. 2008; 111:S75–S81.